1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DC53BFDBB7103A9985257D07006E5BB7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-effective-thought-leader-management-leadership-relationships-and-technology?opendocument
18
19opendocument
203.234.214.179
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Thought Leader Services

Effective Thought Leader Management: Leadership, Relationships and Technology

ID: 5315


Features:

10 Info Graphics

14 Data Graphics

150+ Metrics

3 Narratives


Pages/Slides: 32


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Effective Thought Leader Management: Leadership, Relationships and Technology"


STUDY OVERVIEW

With so many of its activities affecting new product development and performance, medical affairs is recognized as one of the most important functions within pharma organizations. Thought leader management is one of the critical responsibilities of medical affairs groups because companies look to thought leaders to inform and guide clinical programs.

Some of the key components of an effective thought leader management program include its leadership structure and approach to relationship development. Best Practices LLC performed this research study to identify how leading pharma companies structure and organize their thought leader management organizations, to examine the drivers of thought leader management relationships and to highlight new technologies used to maintain relationships.


The benchmark data in this study will help companies find better ways to create effective thought leader management strategies that will enhance and inform a critical aspect of an organization’s operations. This document includes mature and emerging markets segment analysis.


KEY TOPICS

  • Benchmark Participant Demographics
  • Scope, Structure and Leadership
  • Managing Relationships
  • New Technologies

SAMPLE KEY METRICS
  • Number of products involving thought leaders
  • Title of person with oversight responsibility for thought leader management
  • Group with primary oversight for thought leader management
  • Drivers of thought leader management program
  • Importance rating of activities tied to developing thought leader relationships
  • Importance rating of activities tied to maintaining thought leader relationships
  • Value rating of various new technologies used for thought leader interactions in mature markets
  • Value rating of various new technologies used for thought leader interactions in emerging markets

SAMPLE KEY FINDING
  • Number of and Interaction Frequency with thought leader s are the Most Important Management Criteria:  Within 86% of the mature market companies and all of the emerging market companies number of thought leaders and frequency of interaction with thought leaders drive thought leader  management initiatives.
  • MSL Interactions and Clinical Trials Drive TL Relationship Development:  In 70% of the mature market segment and 57% of the emerging market segment, MSL interactions is key to thought leader  relationship development.  In addition, 68% of the mature market and 86% of the emerging market segment reported that Funding Clinical Research is vital for building thought leader relationships. 
METHODOLOGY

Forty survey responses from Medical Affairs leaders at 32 pharmaceutical and medical device companies in the mature market and Emerging Markets. This report captures insights on both Mature and emerging market segments.

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Chemical; Manufacturing; Medical Device; Consumer Products; Diagnostic; Technology


Companies Profiled:
Sanofi; Shire; Astellas; AstraZeneca; Genentech; Dr Reddy's Laboratories; Biogen; Merck; Eli Lilly; Teva Pharmaceutical Industries Ltd; Biocon; United Therapeutics; Amgen; Baxter Healthcare; Acorda Therapeutics; Upsher-Smith; Crescendo Bioscience; ProStrakan; Cubist Pharmaceuticals; Pierre Fabre Medicament; Ironwood; Kadmon Pharmaceuticals; Covidien; Roche; Medtronic; GE Healthcare; Bayer Healthcare; BARD; BD

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.